Latest News and Press Releases

CARMIEL, Israel, July 07, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today the first patient has been dosed in the Company’s phase II clinical...

24-Month Superiority Trial vs. Fabrazyme® for a United States Filing At 12 Months, Interim Analysis of the Superiority Trial Data will be Performed to Test for Non-Inferiority Compared to Fabrazyme...

CARMIEL, Israel, June 02, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), today announced that Moshe Manor, the Company's President and Chief Executive...

Advanced Discussions with FDA regarding SPA for Phase III Clinical Trial of PRX-102 Expected to Commence around Mid-Year Phase II Clinical Trial of PRX-110 in Cystic Fibrosis Patients to...

Net Income of $58 Million Generated mainly due to the Sale of Our Share in Collaboration to Pfizer Strong Cash Position of $76.3 Million Projected to Fund Operations into 2018 Special...

Demonstrated Effectiveness Across All Disease Parameters Including Cardiac and Kidney FunctionsPRX-102 Safe and Well Tolerated With Very Low Formation of AntibodiesCARMIEL, Israel, March 03, 2016 ...

CARMIEL, Israel, Feb. 22, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE:PLX) and (TASE:PLX), announced today that the Company will participate in the SunTrust Robinson Humphrey...

Clear Path for Biologics License Application (BLA) Submission One Short-Term Safety and Efficacy Study Required to Support Full Approval In Parallel, Protalix to Conduct Phase III Head-to-Head...

Net losses narrowed Recent sale of Company's Share in Collaboration and Equity Issuance to Pfizer Yielding a Total of $46 Million to Help Aggressively Push all Three Product...

Significantly Improved PK Characteristics Result in: Higher Active Enzyme Quantities, Induced Immune Tolerance Meaningful Clinical Benefit Demonstrated Across All Key Disease Parameters...